Handok received marketing authorization for the orphan drug ‘Ultromiris 100mg/mL(ravulizumab)’ that is used to treat Paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uraemic syndrome (aHUS) and made a step towards supplying the drug in Korea.

On the 28th, the Ministry of Food and Drug Safety announced that it had granted marketing authorization for the drug.

The drug is a humanized monoclonal antibody (mAb) that specifically binds to the C5 protein and inhibits complement-mediated inflammation and hemolysis, etc.

More specifically, the drug is indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH), and as a treatment for ad